AFMD Affimed Therapeutics: רווח נקי למניה ב-12 החודשים האחרונים

Affimed operates in a defensive sector where demand for healthcare remains independent of macroeconomic conditions. The company generates revenue through royalties and partner payments for access to the ROCK platform. The TTM YoY earnings per share growth rate helps assess the real efficiency of the business, and -37.30 reflects the most recent value of this metric. The ecosystem is based on creating antibody incubators to combat tumors using the body's own immunity.

Year-over-year EPS growth reflects the dynamics of net income per share, stripping the financial result of short-term fluctuations. This metric is calculated as the percentage change in earnings over the last twelve months relative to the same period last year. By analyzing the annual change in net income per share over a rolling period, an investor assesses the sustainability of business scaling. For Affimed (AFMD), this metric demonstrates the effectiveness of commercializing innovative cancer immunotherapy. A positive trend would confirm the successful development of drugs that activate the body's natural killer cells.